Hyundai Bioscience Co (XKRX:048410) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hyundai Bioscience Co's Free Cash Flow for the three months ended in Mar. 2024 was ₩0 Mil. Hyundai Bioscience Co's Revenue for the three months ended in Mar. 2024 was ₩5,050 Mil. Therefore, Hyundai Bioscience Co's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Hyundai Bioscience Co's current FCF Yield % is -0.80%.

The historical rank and industry rank for Hyundai Bioscience Co's FCF Margin % or its related term are showing as below:

XKRX:048410' s FCF Margin % Range Over the Past 10 Years
Min: -230.36 Med: -23.74 Max: -1.38
Current: -58.02

During the past 13 years, the highest FCF Margin % of Hyundai Bioscience Co was -1.38%. The lowest was -230.36%. And the median was -23.74%.

XKRX:048410's FCF Margin % is ranked better than
60.48% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs XKRX:048410: -58.02

Hyundai Bioscience Co FCF Margin % Historical Data

The historical data trend for Hyundai Bioscience Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co FCF Margin % Chart

Hyundai Bioscience Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-12.92

-141.49

-46.53

-230.36

-69.57

Hyundai Bioscience Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-88.99	-16.60	-104.08	-106.17	-

Competitive Comparison of Hyundai Bioscience Co's FCF Margin %

For the Biotechnology subindustry, Hyundai Bioscience Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyundai Bioscience Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's FCF Margin % falls into.

Hyundai Bioscience Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Hyundai Bioscience Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-6595.855	/	9481.385
	=	-69.57 %

Hyundai Bioscience Co's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	5049.774
	=	0.00 %

Hyundai Bioscience Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyundai Bioscience Co (XKRX:048410) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR

Website

http://www.hyundaibioscience.com

Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines